---

The First Multi-Cancer Test Panel Using a Single ​Sample of Blood 

Aristotle® is a multi-cancer test panel that uses mRNA technology to detect multiple cancer signatures from a single sample of blood. Aristotle has been built on our proprietary mRNA technology platform, The Sentinel Principle®, which has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.  

Aristotle needs to be prescribed by a physician and is available through AVRT™, StageZero's comprehensive telehealth program that uses advanced diagnostics and physician supervision to help patients detect cancer in the earliest stages. 

---

ARISTOTLE Panel 

• Breast Cancer
• Ovarian Cancer
• Cervical Cancer
• Endometrial Cancer​
• Liver Cancer
• Colorectal Cancer
• Stomach Cancer
• ​Prostate Cancer
  
• ​Bladder Cancer​​​​​​

---

For Employers & Organizations

Sensitivity and Specificity

Aristotle has been demonstrated to identify sets of gene transcripts capable of classifying subjects as having a specific cancer with a high degree of sensitivity and specificity.

Sources:
1) Aristotle: A single blood test for pan-cancer screening.Adam A Dempsey, Samuel Chao, Dimitri Stamatiou, Tanya Pilcz, Jay Ying, and Robert Burakoff; Journal of Clinical Oncology 2020 38:15_suppl, e15037-e15037
​
Aristotle™  was developed and its performance characteristics determined by Stage Zero Life Sciences, Inc.  It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes. The Aristotle™ test must be ordered by and used only in consultation with a healthcare provider.